Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review

被引：22
作者：
Lauro, Rita [1 ]
Mannino, Federica [1 ]
Irrera, Natasha [1 ,2 ]
Squadrito, Francesco [1 ,2 ]
Altavilla, Domenica [2 ,3 ]
Squadrito, Giovanni [1 ]
Pallio, Giovanni [1 ]
Bitto, Alessandra [1 ,2 ]
机构：
[1] Univ Messina, Dept Clin & Expt Med, Via C Valeria, I-98125 Messina, Italy
[2] Univ Messina, Acad Spin Off Co, SunNutraPharma, Via C Valeria, I-98125 Messina, Italy
[3] Univ Messina, Dept Biomed Dent Morphol & Funct Imaging Sci, Via C Valeria, I-98125 Messina, Italy
来源：
BIOMEDICINES | 2021年 / 9卷 / 12期
关键词：
Inflammatory Bowel Disease; Crohn's disease; ulcerative colitis; infliximab; adalimumab; vedolizumab; ustekinumab; polymorphism; TUMOR-NECROSIS-FACTOR; POLYMORPHISMS PREDICT RESPONSE; CROHNS-DISEASE; FACTOR-ALPHA; GENETIC POLYMORPHISMS; INFLIXIMAB THERAPY; MAINTENANCE THERAPY; TNF; ASSOCIATION; NOD2;
D O I：
10.3390/biomedicines9121748
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Inflammatory Bowel Disease (IBD) comprises a group of disorders, in particular Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation affecting the gastrointestinal tract. The treatment of these conditions is primarily based on anti-inflammatory drugs, although the use of biological drugs with lower side effects quickly increased in the last decade. However, the presence of certain polymorphisms in the population may determine a different outcome in response to therapy, reflecting the heterogeneity of the efficacy in patients. Considering that several studies showed important correlations between genetic polymorphisms and response to biological treatments in IBD patients, this systematic review aims to summarize the pharmacogenetics of biologicals approved for IBD, thus highlighting a possible association between some polymorphisms and drug response. With this purpose, we reviewed PubMed papers published over the past 21 years (2000-2021), using as the search term "drug name and IBD or CD or UC and polymorphisms" to underline the role of pharmacogenetic tests in approaching the disease with a targeted therapy.
引用
收藏
页数：13
相关论文
共 66 条
  • [1] Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
    Anderson, Carl A.
    Boucher, Gabrielle
    Lees, Charlie W.
    Franke, Andre
    D'Amato, Mauro
    Taylor, Kent D.
    Lee, James C.
    Goyette, Philippe
    Imielinski, Marcin
    Latiano, Anna
    Lagace, Caroline
    Scott, Regan
    Amininejad, Leila
    Bumpstead, Suzannah
    Baidoo, Leonard
    Baldassano, Robert N.
    Barclay, Murray
    Bayless, Theodore M.
    Brand, Stephan
    Buening, Carsten
    Colombel, Jean-Frederic
    Denson, Lee A.
    De Vos, Martine
    Dubinsky, Marla
    Edwards, Cathryn
    Ellinghaus, David
    Fehrmann, Rudolf S. N.
    Floyd, James A. B.
    Florin, Timothy
    Franchimont, Denis
    Franke, Lude
    Georges, Michel
    Glas, Juergen
    Glazer, Nicole L.
    Guthery, Stephen L.
    Haritunians, Talin
    Hayward, Nicholas K.
    Hugot, Jean-Pierre
    Jobin, Gilles
    Laukens, Debby
    Lawrance, Ian
    Lemann, Marc
    Levine, Arie
    Libioulle, Cecile
    Louis, Edouard
    McGovern, Dermot P.
    Milla, Monica
    Montgomery, Grant W.
    Morley, Katherine I.
    Mowat, Craig
    [J]. NATURE GENETICS, 2011, 43 (03) : 246 - U94
  • [2] Investigation of the prognostic value of TNF-α gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-α production and apoptosis
    Balog, A
    Klausz, G
    Gál, J
    Molnár, T
    Nagy, F
    Ocsovszky, I
    Gyulai, Z
    Mándi, Y
    [J]. PATHOBIOLOGY, 2004, 71 (05) : 274 - 280
  • [3] Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease
    Bank, S.
    Andersen, P. S.
    Burisch, J.
    Pedersen, N.
    Roug, S.
    Galsgaard, J.
    Turino, S. Y.
    Brodersen, J. B.
    Rashid, S.
    Rasmussen, B. K.
    Avlund, S.
    Olesen, T. B.
    Hoffmann, H. J.
    Thomsen, M. K.
    Thomsen, V. O.
    Frydenberg, M.
    Nexo, B. A.
    Sode, J.
    Vogel, U.
    Andersen, V.
    [J]. PHARMACOGENOMICS JOURNAL, 2014, 14 (06) : 526 - 534
  • [4] Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease
    Bank, Steffen
    Julsgaard, Mette
    Abed, Osama Karim
    Burisch, Johan
    Brodersen, Jacob Broder
    Pedersen, Natalia Konstantinovich
    Gouliaev, Anja
    Ajan, Rullah
    Rasmussen, Ditlev Nytoft
    Grauslund, Camilla Honore
    Roug, Stine
    Galsgaard, Julie
    Finsen, David Sprogoe Hoyer
    Lindby, Karoline
    Sorensen, Jeanette
    Larsen, Lone
    Andersen, Malene Rohr
    Brandslund, Ivan
    Thomassen, Mads
    Green, Anders
    Bojesen, Anders Bo
    Sorensen, Signe Bek
    Vogel, Ulla
    Andersen, Vibeke
    Bergmann, Ann Christina
    Andersen, Paal Skytt
    Rashid, Shaista
    Lund, Britta Ornfelt
    Rasmussen, Britt Kaiser
    Avlund, Sara
    Nielsen, Marie Odum
    Bramstang, Eva Karolina Nilsdotter
    Poulsen, Anja
    Rudbeck-Resdal, Ditte
    Aamann, Luise
    Alexandraki, Maria Joanna
    Foroutani, Ali
    Molzen, Line
    Hatrop, Anders
    Rittig, Charlotte Siggaard
    Stenbog, Elisabeth
    Hedback, Nora Elisabeth
    Nielsen, Rasmus Gaardskaer
    Schiodt, Frank Vinholt
    Carlsen, Katrine
    Dessau, Ram Benny
    Hoffmann, Hans Jurgen
    Nexo, Bjorn Andersen
    Sode, Jacob
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (07) : 890 - 903
  • [5] Barreiro-de Acosta M, 2010, REV ESP ENFERM DIG, V102, P591, DOI 10.4321/s1130-01082010001000005
  • [6] Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases
    Bek, S.
    Nielsen, J. V.
    Bojesen, A. B.
    Franke, A.
    Bank, S.
    Vogel, U.
    Andersen, V.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (06) : 554 - 567
  • [7] Autoimmunity and apoptosis: The Crohn's connection
    Beutler, B
    [J]. IMMUNITY, 2001, 15 (01) : 5 - 14
  • [8] Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease
    Bouma, G
    Crusius, JBA
    Pool, MO
    Kolkman, JJ
    VonBlomberg, BME
    Kostense, PJ
    Giphart, MJ
    Schreuder, GMT
    Meuwissen, SGM
    Pena, AS
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1996, 43 (04) : 456 - 463
  • [9] CD14 Plays a Protective Role in Experimental Inflammatory Bowel Disease by Enhancing Intestinal Barrier Function
    Buchheister, Stephanie
    Buettner, Manuela
    Basic, Marijana
    Noack, Andreas
    Breves, Gerhard
    Buchen, Barbara
    Keubler, Lydia M.
    Becker, Christoph
    Bleich, Andre
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2017, 187 (05) : 1106 - 1120
  • [10] The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis
    Chen, Wenjuan
    Xu, Hui
    Wang, Xiuxiu
    Gu, Junying
    Xiong, Huizi
    Shi, Yuling
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 28 (01) : 146 - 153
1234567